Pharmaceuticals and Drug Development

Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Treatment for: EBV-Positive Post-Transplant Lymphoproliferative Disease Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease THOUSAND OAKS, Calif.–(BUSINESS WIRE) July 17, 2024 — Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic […]
Written by
Body Composition Patterns Linked to Risk of Neurodegenerative Diseases
  1. Pharmaceuticals and Drug Development

Body Composition Patterns Linked to Risk of Neurodegenerative Diseases

Medically reviewed by Drugs.com. By Elana Gotkine HealthDay Reporter WEDNESDAY, July 24, 2024 — Specific body composition patterns are associated with neurodegenerative diseases and brain aging, according to a study published online July 24 in Neurology. Shishi Xu, M.D., Ph.D., from the West China Hospital of Sichuan University in Chengdu, and colleagues conducted a retrospective […]
Written by
  1. Pharmaceuticals and Drug Development

Vilnius University Scientists’ Research on Bacterial Defense from Viruses Was Published in Science

CRISPR-Cas systems provide interference against invading foreign nucleic acids by different mechanisms. In bacteria, several different types of antiviral CRISPR-Cas systems are found, which differ in Cas proteins and their functions. Currently, the best-known Cas9 and Cas12 proteins are widely used as genome editing tools. A team of researchers led by Gintautas Tamulaitis is studying […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Zoryve (roflumilast) cream, 0.15%, for the treatment of mild to moderate atopic […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN

Treatment for: Neurofibromatosis SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the Company has […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

Monthly News Roundup – June 2024

Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 30, 2024. FDA Grants Expanded Approval to Skyrizi for Ulcerative Colitis On June 18th, the U.S. Food and Drug Administration (FDA) approved AbbVie’s Skyrizi (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis (UC). Skyrizi is also approved to treat adults with plaque […]
Written by
  1. Pharmaceuticals and Drug Development

New study from the RVC explores malaria invasion to help develop life-saving vaccine

Malaria is a deadly disease caused by the Plasmodium parasite which infects more than 200 million people a year, causing approximately 600,000 deaths annually worldwide with young children in Africa disproportionately affected. With numbers of infections expected to rise in the coming years due to growing parasite resistance to frontline anti-malarial drugs, there is a […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

FDA Approves Skyrizi (risankizumab-rzaa) for Ulcerative Colitis

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Skyrizi® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn’s disease.3 Skyrizi […]
Written by
Takeda Announces Topline Results of Phase 3 ADMIRE-CD II Trial of Alofisel® (darvadstrocel) in Complex Crohn’s Perianal Fistulas
  1. Pharmaceuticals and Drug Development

New Indication for Motpoly XR (Lacosamide Extended-Release) Capsules for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment)

Generic name: lacosamideTreatment for: Seizures New Indication for Motpoly XR New Indication for Motpoly XR (Lacosamide Extended-Release) Capsules for Primary Generalized Tonic-Clonic Seizures (Adjunctive Treatment) SILVER SPRING, MD. June 7, 2024/FDA Approvals/ — Today, the U.S. Food and Drug Administration (FDA) granted Aucta Pharmaceuticals a prior approval supplemental new drug application for the use of […]
Written by
CDC Urges Clinicians to Remain on the Lookout for Mpox Virus Infections
  1. Pharmaceuticals and Drug Development

CDC Urges Clinicians to Remain on the Lookout for Mpox Virus Infections

Medically reviewed by Drugs.com. By Elana Gotkine HealthDay Reporter THURSDAY, June 6, 2024 — Among emergency department patients evaluated for an mpox-compatible rash, the prevalence of mpox is 1.5 percent, according to research published in the June 6 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report. Carl T. […]
Written by

Good Reads

Mammals didn't walk upright until late—here's what fossils reveal

Mammals didn’t walk upright until late—here’s what fossils reveal

For over a century, scientists have puzzled over a fundamental mystery in our evolutionary history: how did mammals go from sprawling like lizards to striding like cats and dogs? This transition — from a sprawled stance (like a lizard) to an upright (parasagittal) posture — marked a pivotal moment in mammal evolution. While the earliest […]
Written by

A coordinated kinase and phosphatase network regulates Stu2 recruitment to yeast kinetochores

Cells coordinate diverse events at anaphase onset, including separase activation, cohesin cleavage, chromosome separation, and spindle reorganization. Regulation of the XMAP215 family member and microtubule polymerase, Stu2, at the metaphase-anaphase transition determines a redistribution from kinetochores to spindle microtubules. We show that cells modulate Stu2 kinetochore-microtubule localization by Polo-like kinase1/Cdc5-mediated phosphorylation of T866, near the […]
Written by

Worlwide

Mammals didn't walk upright until late—here's what fossils reveal

Mammals didn’t walk upright until late—here’s what fossils reveal

For over a century, scientists have puzzled over a fundamental mystery in our evolutionary history: how did mammals go from sprawling like lizards to striding like cats and dogs? This transition — from a sprawled stance (like a lizard) to an upright (parasagittal) posture — marked a pivotal moment in mammal evolution. While the earliest […]
Written by

A coordinated kinase and phosphatase network regulates Stu2 recruitment to yeast kinetochores

Cells coordinate diverse events at anaphase onset, including separase activation, cohesin cleavage, chromosome separation, and spindle reorganization. Regulation of the XMAP215 family member and microtubule polymerase, Stu2, at the metaphase-anaphase transition determines a redistribution from kinetochores to spindle microtubules. We show that cells modulate Stu2 kinetochore-microtubule localization by Polo-like kinase1/Cdc5-mediated phosphorylation of T866, near the […]
Written by

Trending

Login

Welcome to Life Science News!
"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.